It seems like you are using an older browser, please update your browser for a better user experience.

Stryker Vitoss

Vitoss Bone Graft Substitute

Vitoss Bone Graft Substitute is the #1 selling synthetic bone graft with over 425,000 implantations worldwide.1

The success of Vitoss Bone Graft Substitute is founded on proven results and experience, including numerous human clinical studies (including prospective and peer reviewed).2

Vitoss Bioactive Bone Graft Substitute combines the optimized design of standard Vitoss with a unique bioactive additive that facilitates faster bone remodeling. Vitoss BA2X Bone Graft Substitute, launched in 2011, contains increased levels of bioactive glass and has shown through in-vitro testing to induce two times the deposition of calcium phosphate onto the surface of the implant while retaining the same handling properties as Vitoss BA Pack.3

Vitoss and Vitoss Bioactive Bone Graft Substitute are intended to be used for filling bony voids or gaps of the skeletal system (i.e., the extremities, pelvis, and posterolateral spine), and may be used with saline, autogenous blood, and/or bone marrow.

Additional forms of Vitoss launched in 2012 include Vitoss BBTrauma, available in pack form, exclusively sold for trauma surgery and created with a greater specific surface area of bioactive glass than Vitoss Bioactive, and VitoMatrix, a resorbable, porous Beta-Tricalcium Phosphate bone graft material intended to fill, augment, or reconstruct periodontal or bony defects of the oral and maxillofacial region.

Features & Benefits

Vitoss BA offers many distinct advantages, including its unique structure, porosity, bioactivity, and chemistry that drive the 3-D regeneration of bone and potentially increases the rate of healing as shown in an animal study. 4


Imbibe Bone Marrow Aspiration & Delivery (BMA)

The Imbibe product platform is a family of disposable single use products designed to harvest bone marrow in order to deliver an osteogenic and osteoinductive component to Vitoss bone graft, as well as to assist in the delivery of Vitoss to the surgical site.

The Imbibe products have been designed specifically to enhance the clinical utility of Vitoss Bone Graft Substitute for the surgeon, and to facilitate the aspiration of bone marrow.


Vitoss Bone Graft Substitutes are intended for us as bone void fillers for voids or gaps that are not intrinsic to the stability of the bony structure. Vitoss Bone Graft Substitutes are indicated for use in the treatment of surgically created osseous defects or osseous defects created from traumatic injury to the bone.

Vitoss Bone Graft Substitutes are intended for filling bony voids or gaps of the skeletal system (i.e., the extremities, pelvis and posterolateral spine) and may be combines with saline, autogenous blood, and/or bone marrow. Following placement in the bony void or gap, the scaffold resorbs and is replaced with bone during the healing process. The osteostimulatory nature of Vitoss BA and Vitoss BA2X has not been correlated to human clinical experience.


1 – Stryker Orthobiologics Internal Sales Data, April 2012.

2 – Vitoss Bibliography, P/N 5606-0117 Rev. 00, 2010.

3 – Millennium Research Group: US Markets for Orthopedic Biomaterials 2010.

4 – Brown, LS, Darmoc, MM, Owsiany, RS, Clineff, TD, Improvements in healing with a Bioactive Bone Graft Substitute in a Canine Metaphyseal Defect. 55th Annual Meeting of the Orthopaedic Research Society, 2009.

5 – Orthovita Test Report P/N 10570-0003R.

6 – Motomiya, M., et al., Effect of Hydroxyapatite Porous Characteristics on Healing Outcomes in Rabbit Posterolateral Spinal Fusion Model. Eurpean Spine Journal, 207; 16:2215-2224.

7 – Orthovita Test Report P/N 1070-0008R.

8 – Characteristics of Vitoss BA Product.

9 – Hench, L.L., Splinter, R.J., and Allen, W.C., Bonding Mechanisms at the Interface of Ceramic Prosthetic Materials. Journal of Biomedical Materials Research, 1971; 2(1): 117-141.

10- Hench, L.L., Paschall, H.A., Direct Chemical Bond of Bioactive Glass-Ceramic Materials to Bone and Muscle. Journal of Biomedical Materials Research, 1973; 4:25-42.

11 – Gross, U., The Interface of Various Glasses anad Glass Ceramics with a Bony Implantation Bed. Journal of Biomedical Materials Research, 1985; 19:251-257.

12 - Sanders, D.M., Hench, L.L., Mechanisms of Glass Corrosion. Journal of American Cermamic Society. 1973; 56(7); 373-377.

13 – Hench, L.L., Characterization of Glass Corrosion and Durability. Journal of Non-Crystalline Solids, 1975; 19: 27-39.

14 – Ogino, M., Hench, L.L., Formation of Calcium Phosphate Films on Silicate Glasses. Journal of Non-Crystalline Solids, 1980; 38 and 39: 673-678.

15 – Vrouwenvelder, W.C.A., Histological and Biochemical Evaluation of Osteoblasts Cultured on Bioactive Glass, Hydroxyapatite, Titanium Alloy, and Stainless Stell. Journal of Biomedical Materials Research, 1993 Apr; 27(4): 465-75.

16 – Hench, L.L., The Story of Bioglass, Journal of Materials Science: Materials in Medicine, 2006 Nov; 17(11): 967-78.

17 – Oonishi, H., et al., Particulate Bioglass Compared with Hydroxyapatite as a Bone Graft Substitute. Clinical Orthopaedics and Related Research, 1997 Jan; 334: 316-25.

18 – Xynos, I.D., Edgar, A.J., Buttery, L.D.K., Hench, L.L., and Polak, J.M., Ionic Products of Bioactive Glass Dissolution Increase Proliferation of Human Osteoblasts and Induce Insulin-like Growth Factor II mRNA Expression and Protein Synthesis. Biochemical and Biophysical Research Communications, 2000 September 24; 276(2): 461-5.

19 – Ankker et al, Ultraporous Beta-Tricalcium Phosphate is Well Incorporated in Small Cavitary Defects. Clinical Orthopaedics and Related Research, 2005 May; 434: 251-7.